ArticleCureus2022

Evaluating the Optimal Sequence of Treatment With EGFR Inhibitors and Bevacizumab in RAS Wild-Type Metastatic Colorectal Cancer.

Diana Martins et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.